JW Therapeutics Announces Initiation of Clinical Study of JWAT...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SHANGHAI, July 4, 2022 /PRNewswire-AsiaNet/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of phase I clinical study of JWATM204 in patients wit...
Authors: LATEST ASIANET NEWS RELEASES